StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 13 Feb 2026 10:57:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form SCHEDULE 13G/A PRECIGEN, INC. Filed by: Patient Capital Management, LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PRECIGEN%2C+INC.+++++++++++++++++++++++++Filed+by%3A+Patient+Capital+Management%2C+LLC/25997308.html si-local-file:///var/storage/secattach/20260213/25997308.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PRECIGEN%2C+INC.+++++++++++++++++++++++++Filed+by%3A+Patient+Capital+Management%2C+LLC/25997308.html Fri, 13 Feb 2026 10:57:00 -0500 O.13607936 PGEN Form SCHEDULE 13G/A PRECIGEN, INC. Filed by: Patient Capital Management, LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PRECIGEN%2C+INC.+++++++++++++++++++++++++Filed+by%3A+Patient+Capital+Management%2C+LLC/25997308.html si-local-file:///var/storage/secattach/20260213/25997308.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PRECIGEN%2C+INC.+++++++++++++++++++++++++Filed+by%3A+Patient+Capital+Management%2C+LLC/25997308.html Fri, 13 Feb 2026 10:57:00 -0500 O.13607936 PGEN Form SCHEDULE 13G PRECIGEN, INC. Filed by: Point72 Asset Management, L.P. http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++PRECIGEN%2C+INC.+++++++++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./25887094.html si-local-file:///var/storage/secattach/20260123/25887094.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++PRECIGEN%2C+INC.+++++++++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./25887094.html Fri, 23 Jan 2026 16:06:00 -0500 O.13607936 PGEN Form SCHEDULE 13G PRECIGEN, INC. Filed by: Point72 Asset Management, L.P. http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++PRECIGEN%2C+INC.+++++++++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./25887094.html si-local-file:///var/storage/secattach/20260123/25887094.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++PRECIGEN%2C+INC.+++++++++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./25887094.html Fri, 23 Jan 2026 16:06:00 -0500 O.13607936 PGEN Medical experts recommend PAPZIMEOS as first-line RRP treatment, Precigen says http://www.streetinsider.com/Corporate+News/Medical+experts+recommend+PAPZIMEOS+as+first-line+RRP+treatment%2C+Precigen+says/25865012.html <p>A consensus paper by 16 physicians published in The Laryngoscope recommends PAPZIMEOS as the standard of care first-line treatment for adults with recurrent respiratory papillomatosis, according to Precigen Inc. (NASDAQ: PGEN).</p><p>The expert consensus paper, sponsored by the Recurrent Respiratory Papillomatosis Foundation, represents a shift from surgical intervention to treating the underlying HPV infection that causes RRP. The recommendations are based on clinical experience, published literature, and the availability of PAPZIMEOS, which received FDA approval as the first HPV-specific immunotherapy for RRP.</p><p>RRP is a rare disease affecting the respiratory tract caused by chronic HPV 6 or HPV 11 infection. The condition http://www.streetinsider.com/Corporate+News/Medical+experts+recommend+PAPZIMEOS+as+first-line+RRP+treatment%2C+Precigen+says/25865012.html Tue, 20 Jan 2026 08:06:08 -0500 PGEN New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis http://www.streetinsider.com/Press+Releases/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html <div class="xn-content"> <ul type="disc"><li><i>Independent, expert-led consensus paper, sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span>, reflects the recommendation of 16 leading physicians in the field of RRP</i></li><li><i>Consensus paper recommends PAPZIMEOS as the <i><span>new standard of care </span></i>first-line treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4598765-1&h=1544866063&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the publication of a new expert consensus paper sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF) and authored by 16 http://www.streetinsider.com/Press+Releases/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html Tue, 20 Jan 2026 08:05:00 -0500 A.22771047 O.13607936 O.20042566 PGEN New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis http://www.streetinsider.com/Press+Releases/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html <div class="xn-content"> <ul type="disc"><li><i>Independent, expert-led consensus paper, sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span>, reflects the recommendation of 16 leading physicians in the field of RRP</i></li><li><i>Consensus paper recommends PAPZIMEOS as the <i><span>new standard of care </span></i>first-line treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4598765-1&h=1544866063&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the publication of a new expert consensus paper sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF) and authored by 16 http://www.streetinsider.com/Press+Releases/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html Tue, 20 Jan 2026 08:05:00 -0500 A.22771047 O.13607936 O.20042566 PGEN New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis http://www.streetinsider.com/Press+Releases/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html <div class="xn-content"> <ul type="disc"><li><i>Independent, expert-led consensus paper, sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span>, reflects the recommendation of 16 leading physicians in the field of RRP</i></li><li><i>Consensus paper recommends PAPZIMEOS as the <i><span>new standard of care </span></i>first-line treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4598765-1&h=1544866063&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the publication of a new expert consensus paper sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF) and authored by 16 http://www.streetinsider.com/Press+Releases/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html Tue, 20 Jan 2026 08:05:00 -0500 A.22771047 O.13607936 O.20042566 PGEN New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis http://www.streetinsider.com/Press+Releases/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html <div class="xn-content"> <ul type="disc"><li><i>Independent, expert-led consensus paper, sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span>, reflects the recommendation of 16 leading physicians in the field of RRP</i></li><li><i>Consensus paper recommends PAPZIMEOS as the <i><span>new standard of care </span></i>first-line treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4598765-1&h=1544866063&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the publication of a new expert consensus paper sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF) and authored by 16 http://www.streetinsider.com/Press+Releases/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html Tue, 20 Jan 2026 08:05:00 -0500 A.22771047 O.13607936 O.20042566 PGEN New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis http://www.streetinsider.com/PRNewswire/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html <div class="xn-content"> <ul type="disc"><li><i>Independent, expert-led consensus paper, sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span>, reflects the recommendation of 16 leading physicians in the field of RRP</i></li><li><i>Consensus paper recommends PAPZIMEOS as the <i><span>new standard of care </span></i>first-line treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4598765-1&h=1544866063&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the publication of a new expert consensus paper sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF) and authored by 16 http://www.streetinsider.com/PRNewswire/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html Tue, 20 Jan 2026 08:05:00 -0500 A.22771047 O.13607936 O.20042566 PGEN New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis http://www.streetinsider.com/PRNewswire/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html <div class="xn-content"> <ul type="disc"><li><i>Independent, expert-led consensus paper, sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span>, reflects the recommendation of 16 leading physicians in the field of RRP</i></li><li><i>Consensus paper recommends PAPZIMEOS as the <i><span>new standard of care </span></i>first-line treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4598765-1&h=1544866063&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the publication of a new expert consensus paper sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF) and authored by 16 http://www.streetinsider.com/PRNewswire/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html Tue, 20 Jan 2026 08:05:00 -0500 A.22771047 O.13607936 O.20042566 PGEN New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis http://www.streetinsider.com/PRNewswire/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html <div class="xn-content"> <ul type="disc"><li><i>Independent, expert-led consensus paper, sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span>, reflects the recommendation of 16 leading physicians in the field of RRP</i></li><li><i>Consensus paper recommends PAPZIMEOS as the <i><span>new standard of care </span></i>first-line treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4598765-1&h=1544866063&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the publication of a new expert consensus paper sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF) and authored by 16 http://www.streetinsider.com/PRNewswire/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html Tue, 20 Jan 2026 08:05:00 -0500 A.22771047 O.13607936 O.20042566 PGEN New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis http://www.streetinsider.com/PRNewswire/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html <div class="xn-content"> <ul type="disc"><li><i>Independent, expert-led consensus paper, sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span>, reflects the recommendation of 16 leading physicians in the field of RRP</i></li><li><i>Consensus paper recommends PAPZIMEOS as the <i><span>new standard of care </span></i>first-line treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4598765-1&h=1544866063&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the publication of a new expert consensus paper sponsored by the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF) and authored by 16 http://www.streetinsider.com/PRNewswire/New+Expert+Consensus+Published+in+The+Laryngoscope+Recommends+PAPZIMEOS+%28zopapogene+imadenovec%29+as+the+New+Standard+of+Care+First-Line+Treatment+for+Adults+with+Recurrent+Respiratory+Papillomatosis/25865001.html Tue, 20 Jan 2026 08:05:00 -0500 A.22771047 O.13607936 O.20042566 PGEN Precigen reports 200 patients enrolled for FDA-approved RRP therapy http://www.streetinsider.com/Corporate+News/Precigen+reports+200+patients+enrolled+for+FDA-approved+RRP+therapy/25834620.html <p>Precigen Inc. (NASDAQ: PGEN) reported that patient enrollment for its FDA-approved therapy PAPZIMEOS has surpassed 200 registered patients, doubling since November. The company received FDA approval for PAPZIMEOS in August 2025 as the first treatment for adults with recurrent respiratory papillomatosis (RRP).</p><p>The therapy is currently being prescribed nationwide with patients receiving treatment, according to the company's statement. Private health plan coverage has reached approximately 170 million lives, including coverage under Medicare and Medicaid.</p><p>The European Medicines Agency has validated the Marketing Authorization Application for PAPZIMEOS for treating adults with RRP, following a submission in November 2025.</p><p>"Commercialization of PAPZIMEOS is proceeding as http://www.streetinsider.com/Corporate+News/Precigen+reports+200+patients+enrolled+for+FDA-approved+RRP+therapy/25834620.html Mon, 12 Jan 2026 08:04:15 -0500 PGEN Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html <div class="xn-content"> <ul type="disc"><li><i><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen</span> transitioned to a commercial stage company with the US approval of PAPZIMEOS in <chron>August 2025</chron>, the first-and-only FDA-approved treatment for adults with RRP </i></li><li><i>PAPZIMEOS commercialization is well underway and PAPZIMEOS is being prescribed nationwide, with patients actively receiving treatment</i></li><li><i>PAPZIMEOS patient hub enrollment has surpassed 200 registered patients, doubling since November, and reflecting significant demand at both major medical centers and community practices</i></li><li><i><span>Patient access continues to expand, with private health plan coverage now at approximately 170 million US lives, including the majority of leading insurers. PAPZIMEOS is also covered under Medicare and Medicaid</span></i></li><li><i>The <span value="ACORN:3106670068" http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html Mon, 12 Jan 2026 08:00:00 -0500 A.06822034 A.24194066 A.31066700 O.13607936 O.20026344 O.20250683 O.22422661 PGEN Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html <div class="xn-content"> <ul type="disc"><li><i><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen</span> transitioned to a commercial stage company with the US approval of PAPZIMEOS in <chron>August 2025</chron>, the first-and-only FDA-approved treatment for adults with RRP </i></li><li><i>PAPZIMEOS commercialization is well underway and PAPZIMEOS is being prescribed nationwide, with patients actively receiving treatment</i></li><li><i>PAPZIMEOS patient hub enrollment has surpassed 200 registered patients, doubling since November, and reflecting significant demand at both major medical centers and community practices</i></li><li><i><span>Patient access continues to expand, with private health plan coverage now at approximately 170 million US lives, including the majority of leading insurers. PAPZIMEOS is also covered under Medicare and Medicaid</span></i></li><li><i>The <span value="ACORN:3106670068" http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html Mon, 12 Jan 2026 08:00:00 -0500 A.06822034 A.24194066 A.31066700 O.13607936 O.20026344 O.20250683 O.22422661 PGEN Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html <div class="xn-content"> <ul type="disc"><li><i><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen</span> transitioned to a commercial stage company with the US approval of PAPZIMEOS in <chron>August 2025</chron>, the first-and-only FDA-approved treatment for adults with RRP </i></li><li><i>PAPZIMEOS commercialization is well underway and PAPZIMEOS is being prescribed nationwide, with patients actively receiving treatment</i></li><li><i>PAPZIMEOS patient hub enrollment has surpassed 200 registered patients, doubling since November, and reflecting significant demand at both major medical centers and community practices</i></li><li><i><span>Patient access continues to expand, with private health plan coverage now at approximately 170 million US lives, including the majority of leading insurers. PAPZIMEOS is also covered under Medicare and Medicaid</span></i></li><li><i>The <span value="ACORN:3106670068" http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html Mon, 12 Jan 2026 08:00:00 -0500 A.06822034 A.24194066 A.31066700 O.13607936 O.20026344 O.20250683 O.22422661 PGEN Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html <div class="xn-content"> <ul type="disc"><li><i><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen</span> transitioned to a commercial stage company with the US approval of PAPZIMEOS in <chron>August 2025</chron>, the first-and-only FDA-approved treatment for adults with RRP </i></li><li><i>PAPZIMEOS commercialization is well underway and PAPZIMEOS is being prescribed nationwide, with patients actively receiving treatment</i></li><li><i>PAPZIMEOS patient hub enrollment has surpassed 200 registered patients, doubling since November, and reflecting significant demand at both major medical centers and community practices</i></li><li><i><span>Patient access continues to expand, with private health plan coverage now at approximately 170 million US lives, including the majority of leading insurers. PAPZIMEOS is also covered under Medicare and Medicaid</span></i></li><li><i>The <span value="ACORN:3106670068" http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html Mon, 12 Jan 2026 08:00:00 -0500 A.06822034 A.24194066 A.31066700 O.13607936 O.20026344 O.20250683 O.22422661 PGEN Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html <div class="xn-content"> <ul type="disc"><li><i><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen</span> transitioned to a commercial stage company with the US approval of PAPZIMEOS in <chron>August 2025</chron>, the first-and-only FDA-approved treatment for adults with RRP </i></li><li><i>PAPZIMEOS commercialization is well underway and PAPZIMEOS is being prescribed nationwide, with patients actively receiving treatment</i></li><li><i>PAPZIMEOS patient hub enrollment has surpassed 200 registered patients, doubling since November, and reflecting significant demand at both major medical centers and community practices</i></li><li><i><span>Patient access continues to expand, with private health plan coverage now at approximately 170 million US lives, including the majority of leading insurers. PAPZIMEOS is also covered under Medicare and Medicaid</span></i></li><li><i>The <span value="ACORN:3106670068" http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html Mon, 12 Jan 2026 08:00:00 -0500 A.06822034 A.24194066 A.31066700 O.13607936 O.20026344 O.20250683 O.22422661 PGEN Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html <div class="xn-content"> <ul type="disc"><li><i><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen</span> transitioned to a commercial stage company with the US approval of PAPZIMEOS in <chron>August 2025</chron>, the first-and-only FDA-approved treatment for adults with RRP </i></li><li><i>PAPZIMEOS commercialization is well underway and PAPZIMEOS is being prescribed nationwide, with patients actively receiving treatment</i></li><li><i>PAPZIMEOS patient hub enrollment has surpassed 200 registered patients, doubling since November, and reflecting significant demand at both major medical centers and community practices</i></li><li><i><span>Patient access continues to expand, with private health plan coverage now at approximately 170 million US lives, including the majority of leading insurers. PAPZIMEOS is also covered under Medicare and Medicaid</span></i></li><li><i>The <span value="ACORN:3106670068" http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html Mon, 12 Jan 2026 08:00:00 -0500 A.06822034 A.24194066 A.31066700 O.13607936 O.20026344 O.20250683 O.22422661 PGEN Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html <div class="xn-content"> <ul type="disc"><li><i><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen</span> transitioned to a commercial stage company with the US approval of PAPZIMEOS in <chron>August 2025</chron>, the first-and-only FDA-approved treatment for adults with RRP </i></li><li><i>PAPZIMEOS commercialization is well underway and PAPZIMEOS is being prescribed nationwide, with patients actively receiving treatment</i></li><li><i>PAPZIMEOS patient hub enrollment has surpassed 200 registered patients, doubling since November, and reflecting significant demand at both major medical centers and community practices</i></li><li><i><span>Patient access continues to expand, with private health plan coverage now at approximately 170 million US lives, including the majority of leading insurers. PAPZIMEOS is also covered under Medicare and Medicaid</span></i></li><li><i>The <span value="ACORN:3106670068" http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html Mon, 12 Jan 2026 08:00:00 -0500 A.06822034 A.24194066 A.31066700 O.13607936 O.20026344 O.20250683 O.22422661 PGEN Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html <div class="xn-content"> <ul type="disc"><li><i><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen</span> transitioned to a commercial stage company with the US approval of PAPZIMEOS in <chron>August 2025</chron>, the first-and-only FDA-approved treatment for adults with RRP </i></li><li><i>PAPZIMEOS commercialization is well underway and PAPZIMEOS is being prescribed nationwide, with patients actively receiving treatment</i></li><li><i>PAPZIMEOS patient hub enrollment has surpassed 200 registered patients, doubling since November, and reflecting significant demand at both major medical centers and community practices</i></li><li><i><span>Patient access continues to expand, with private health plan coverage now at approximately 170 million US lives, including the majority of leading insurers. PAPZIMEOS is also covered under Medicare and Medicaid</span></i></li><li><i>The <span value="ACORN:3106670068" http://www.streetinsider.com/Press+Releases/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html Mon, 12 Jan 2026 08:00:00 -0500 A.06822034 A.24194066 A.31066700 O.13607936 O.20026344 O.20250683 O.22422661 PGEN Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference http://www.streetinsider.com/PRNewswire/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html <div class="xn-content"> <ul type="disc"><li><i><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen</span> transitioned to a commercial stage company with the US approval of PAPZIMEOS in <chron>August 2025</chron>, the first-and-only FDA-approved treatment for adults with RRP </i></li><li><i>PAPZIMEOS commercialization is well underway and PAPZIMEOS is being prescribed nationwide, with patients actively receiving treatment</i></li><li><i>PAPZIMEOS patient hub enrollment has surpassed 200 registered patients, doubling since November, and reflecting significant demand at both major medical centers and community practices</i></li><li><i><span>Patient access continues to expand, with private health plan coverage now at approximately 170 million US lives, including the majority of leading insurers. PAPZIMEOS is also covered under Medicare and Medicaid</span></i></li><li><i>The <span value="ACORN:3106670068" http://www.streetinsider.com/PRNewswire/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html Mon, 12 Jan 2026 08:00:00 -0500 A.06822034 A.24194066 A.31066700 O.13607936 O.20026344 O.20250683 O.22422661 PGEN Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference http://www.streetinsider.com/PRNewswire/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html <div class="xn-content"> <ul type="disc"><li><i><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen</span> transitioned to a commercial stage company with the US approval of PAPZIMEOS in <chron>August 2025</chron>, the first-and-only FDA-approved treatment for adults with RRP </i></li><li><i>PAPZIMEOS commercialization is well underway and PAPZIMEOS is being prescribed nationwide, with patients actively receiving treatment</i></li><li><i>PAPZIMEOS patient hub enrollment has surpassed 200 registered patients, doubling since November, and reflecting significant demand at both major medical centers and community practices</i></li><li><i><span>Patient access continues to expand, with private health plan coverage now at approximately 170 million US lives, including the majority of leading insurers. PAPZIMEOS is also covered under Medicare and Medicaid</span></i></li><li><i>The <span value="ACORN:3106670068" http://www.streetinsider.com/PRNewswire/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html Mon, 12 Jan 2026 08:00:00 -0500 A.06822034 A.24194066 A.31066700 O.13607936 O.20026344 O.20250683 O.22422661 PGEN Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference http://www.streetinsider.com/PRNewswire/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html <div class="xn-content"> <ul type="disc"><li><i><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen</span> transitioned to a commercial stage company with the US approval of PAPZIMEOS in <chron>August 2025</chron>, the first-and-only FDA-approved treatment for adults with RRP </i></li><li><i>PAPZIMEOS commercialization is well underway and PAPZIMEOS is being prescribed nationwide, with patients actively receiving treatment</i></li><li><i>PAPZIMEOS patient hub enrollment has surpassed 200 registered patients, doubling since November, and reflecting significant demand at both major medical centers and community practices</i></li><li><i><span>Patient access continues to expand, with private health plan coverage now at approximately 170 million US lives, including the majority of leading insurers. PAPZIMEOS is also covered under Medicare and Medicaid</span></i></li><li><i>The <span value="ACORN:3106670068" http://www.streetinsider.com/PRNewswire/Precigen+Showcases+Rapid+Commercialization+Momentum+and+Growing+Market+Adoption+of+First-and-Only+FDA-Approved+Therapy+for+RRP+at+the+44th+Annual+J.P.+Morgan+Healthcare+Conference/25834498.html Mon, 12 Jan 2026 08:00:00 -0500 A.06822034 A.24194066 A.31066700 O.13607936 O.20026344 O.20250683 O.22422661 PGEN